Genmab A (GMAB) Receivables (2018 - 2026)

Genmab A (GMAB) has reported Receivables for 6 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 28.66% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (up 28.66% YoY), and the FY2025 full-year result was $1.2 billion, up 85.14% from the prior year.
• Receivables grew to $1.3 billion in Q2 2026 per GMAB's latest filing, from $968.0 million in the prior quarter.
• Across five years, Receivables topped out at $1.3 billion in Q2 2026 and bottomed at $597.7 million in Q4 2023.
• Historically, Receivables has averaged $948.3 million across 4 years, with a median of $983.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables climbed 8.08% in 2024, then soared 85.14% in 2025.
• Over 4 years, Receivables stood at $597.7 million in 2023, then gained by 8.08% to $646.0 million in 2024, then surged by 85.14% to $1.2 billion in 2025, then gained by 7.36% to $1.3 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $1.3 billion, $968.0 million, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.